Email Updates

You are here

AVAC in the News

  • AVAC Executive Director Mitchell Warren speaks with Feature Story News about recent developments with long-acting injectables. One injection of anti-retrovirals was shown to protect lab monkeys from HIV for several weeks.

    March 5, 2014
    Feature Story News
  • Researchers are reporting that injections of long-lasting AIDS drugs protected monkeys for weeks against infection, a finding that could lead to a major breakthrough in preventing the disease in humans.

    March 4, 2014
    New York Times
  • A tiny coffee shop table can barely contain Reid Rubsamen, whose restless energy nearly propels him out of his chair as he talks about the Immunity Project, his initiative to crowd-source money to make a new HIV vaccine.

    February 10, 2014
    Nature
  • The bio of the executive director of AIDS Vaccine Advocacy Coalition (AVAC) says he "uses public education, policy analysis, advocacy and community mobilization to accelerate the ethical development and global delivery of AIDS vaccines and other HIV prevention options" (such as microbicides). We couldn't say it better ourselves. So we didn't try.

    January 7, 2014
    POZ
  • An AIDS advocacy group says donors and researchers need to work smarter and faster to introduce prevention methods that people will actually use. AVAC says not enough has been done to capitalize on lessons learned from recent studies. AVAC Executive Director Mitchell Warren said that it’s time for a “reality check” in HIV prevention research.

    December 9, 2013
    General
    Voice of America
  • As a result of work funded through the President's Emergency Plan for AIDS Relief (PEPFAR), an estimated 1 million children have been born free of HIV and 6.7 million people now receive lifesaving anti-retroviral treatment.

    December 6, 2013
    Huffington Post
  • Increased attention to the delivery of HIV prevention and treatment programmes is needed to prepare communities for a potential roll-out of a vaccine, which will most probably be partially-effective, experts say. “How to deliver a 31 percent effective vaccine - it’s hard stuff, it’s uncharted territory, and it’s un-costed territory,” Mitchell Warren, executive director of the New York-based NGO AIDS Vaccine Advocacy Coalition (AVAC), told IRIN.

    October 23, 2013
    IRIN
  • About a dozen countries hit hard by AIDS have reached a “tipping point” that means they are winning their battles against the disease, according to a new analysis.

    October 7, 2013
    New York Times
  • In November, 2010, the New England Journal of Medicine published the results of a three-year clinical trial, funded by the National Institutes of Health, announcing the arrival of a treatment that could reduce the risk of contracting H.I.V. by more than ninety per cent. But, in fact, adoption of the drug has been slow. According to Dawn Smith, a biomedical interventions implementation officer in the C.D.C.’s epidemiology branch, at least half a million Americans are good candidates for PrEP—meaning that they are at high risk for contracting H.I.V.

    October 1, 2013
    The New Yorker
  • Although we have yet to discover a vaccine to prevent HIV infection or lower viral load, there are currently 30 candidates moving forward in clinical trials across the world. AVAC: Global Advocacy for HIV Prevention’s Executive Director Mitchell Warren spoke to EDGE about current human clinical trials in Thailand and South Africa that show promise.

    September 27, 2013
    Edge on the Net

Pages